晚期肝细胞癌-话题@MedSci

#晚期肝细胞癌#

57篇内容 | 2837人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2208496, encodeId=d1d1220849613, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a> <a href='/topic/show?id=fc2be734870' target=_blank style='color:#2F92EE;'>#纳武利尤单抗#</a> <a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=ASCO 2024：与仑伐替尼或索拉非尼相比，纳武利尤单抗联合伊匹木单抗一线治疗晚期肝细胞癌患者可显著改善总生存期（CheckMate -9DW 3期研究）, objectType=article, longId=828832, objectId=40758288325e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240605/1717570406384_5579292.jpg, objectUrl=/article/show_article.do?id=40758288325e, replyNumber=0, likeNumber=170, createdTime=2024-06-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=40758288325e, moduleTitle=ASCO 2024：与仑伐替尼或索拉非尼相比，纳武利尤单抗联合伊匹木单抗一线治疗晚期肝细胞癌患者可显著改善总生存期（CheckMate -9DW 3期研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40758288325e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2201967, encodeId=5a35220196e98, content=<a href='/topic/show?id=0a9e922085f' target=_blank style='color:#2F92EE;'>#贝伐珠单抗#</a> <a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a> <a href='/topic/show?id=333a6802212' target=_blank style='color:#2F92EE;'>#特瑞普利单抗#</a>, objectTitle=CLIN CANCER RES | 特瑞普利单抗联合贝伐珠单抗作为晚期肝细胞癌一线治疗的II期临床试验, objectType=article, longId=824480, objectId=893682448052, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240505/1714905641060_6145188.png, objectUrl=/article/show_article.do?id=893682448052, replyNumber=0, likeNumber=91, createdTime=2024-05-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=893682448052, moduleTitle=CLIN CANCER RES | 特瑞普利单抗联合贝伐珠单抗作为晚期肝细胞癌一线治疗的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=893682448052)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2194692, encodeId=b97e219469281, content=<a href='/topic/show?id=34b54848271' target=_blank style='color:#2F92EE;'>#帕博利珠单抗#</a> <a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=JCO：疗效良好且安全可控：帕博利珠单抗二线治疗亚洲晚期HCC患者（III期临床研究）, objectType=article, longId=817686, objectId=311d81e68687, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240321/1711032582542_6145188.jpg, objectUrl=/article/show_article.do?id=311d81e68687, replyNumber=0, likeNumber=81, createdTime=2024-03-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=311d81e68687, moduleTitle=JCO：疗效良好且安全可控：帕博利珠单抗二线治疗亚洲晚期HCC患者（III期临床研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=311d81e68687)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2178613, encodeId=dd5c21e861388, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a> <a href='/topic/show?id=6bf49e844e9' target=_blank style='color:#2F92EE;'>#阿替利珠单抗#</a>, objectTitle=读书报告 | 晚期肝细胞癌系统治疗指南建议的批判性评价, objectType=article, longId=807802, objectId=732580e8024b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679867576310_4754896.jpeg, objectUrl=/article/show_article.do?id=732580e8024b, replyNumber=0, likeNumber=101, createdTime=2024-01-01, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=732580e8024b, moduleTitle=读书报告 | 晚期肝细胞癌系统治疗指南建议的批判性评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=732580e8024b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2175197, encodeId=0bba21e5197e4, content=有几项研究显示，<a href='/topic/show?id=5fae39e738a' target=_blank style='color:#2F92EE;'>#咖啡#</a>、<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>、<a href='/topic/show?id=2f9525346ca' target=_blank style='color:#2F92EE;'>#他汀类药物#</a>和<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>的使用均与<a href='/topic/show?id=735a81364b7' target=_blank style='color:#2F92EE;'>#肝细胞癌#</a>风险降低有关。对于需要使用<a href='/topic/show?id=0de5290588c' target=_blank style='color:#2F92EE;'>#免疫检查点抑制剂#</a>治疗的<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>，一线治疗推荐方案为<a href='/topic/show?id=6bf49e844e9' target=_blank style='color:#2F92EE;'>#阿替利珠单抗#</a>联合<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>。若患者存在胃食管和/或胃肠道出血高风险或其他贝伐珠单抗禁忌证，<a href='/topic/show?id=7b2910612398' target=_blank style='color:#2F92EE;'>#度伐利尤单抗#</a>+<a href='/topic/show?id=ba5c1e796cf' target=_blank style='color:#2F92EE;'>#Tremelimumab#</a>可能是更合适的选择。对于存在使用免疫检查点抑制剂禁忌证的患者，如患有自身免疫性疾病或肝移植后接受免疫抑制剂治疗的患者，推荐一线治疗选择<a href='/topic/show?id=341f25314f1' target=_blank style='color:#2F92EE;'>#仑伐替尼#</a>或<a href='/topic/show?id=1e47e697672' target=_blank style='color:#2F92EE;'>#索拉非尼#</a>, objectTitle=Nature子刊：全球超80万人死于肝癌！咖啡、阿司匹林、他汀、二甲双胍或可预防, objectType=article, longId=799397, objectId=e489e993971a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing-D3K6QME.jpg, objectUrl=/article/show_article.do?id=e489e993971a, replyNumber=0, likeNumber=122, createdTime=2023-12-16, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=e489e993971a, moduleTitle=Nature子刊：全球超80万人死于肝癌！咖啡、阿司匹林、他汀、二甲双胍或可预防, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e489e993971a)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1368226, encodeId=d626136822650, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Clin Cancer Res：派姆单抗单药治疗初治晚期肝细胞癌, objectType=article, longId=726090, objectId=0c95e260900a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c95e260900a, replyNumber=0, likeNumber=58, createdTime=2022-05-05, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c95e260900a, moduleTitle=Clin Cancer Res：派姆单抗单药治疗初治晚期肝细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c95e260900a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368225, encodeId=697f13682251e, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Clin Cancer Res：Pembrolizumab单药治疗晚期肝细胞癌的效果, objectType=article, longId=724681, objectId=ae69e2468173, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae69e2468173, replyNumber=0, likeNumber=95, createdTime=2022-04-22, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae69e2468173, moduleTitle=Clin Cancer Res：Pembrolizumab单药治疗晚期肝细胞癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae69e2468173)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368224, encodeId=b3fb136822452, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=BMC Cancer：仑伐替尼联合PD-1抑制剂治疗晚期肝细胞癌的真实世界疗效, objectType=article, longId=301506, objectId=0b2e301506ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b2e301506ca, replyNumber=0, likeNumber=93, createdTime=2022-03-25, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b2e301506ca, moduleTitle=BMC Cancer：仑伐替尼联合PD-1抑制剂治疗晚期肝细胞癌的真实世界疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b2e301506ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368223, encodeId=cc1f1368223ce, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Clin Cancer Res：可预测晚期肝细胞癌对信迪利单抗联合IBI305治疗反应的生物标志物！, objectType=article, longId=300902, objectId=92d130090243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92d130090243, replyNumber=0, likeNumber=104, createdTime=2022-03-17, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92d130090243, moduleTitle=Clin Cancer Res：可预测晚期肝细胞癌对信迪利单抗联合IBI305治疗反应的生物标志物！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92d130090243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368222, encodeId=d60f136822259, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Liver Cancer：仑伐替尼联合或不联合药物洗脱微球经动脉化疗栓塞治疗不可切除晚期肝细胞癌的疗效, objectType=article, longId=300542, objectId=048f300542db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=048f300542db, replyNumber=0, likeNumber=92, createdTime=2022-03-13, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=048f300542db, moduleTitle=Liver Cancer：仑伐替尼联合或不联合药物洗脱微球经动脉化疗栓塞治疗不可切除晚期肝细胞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=048f300542db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368221, encodeId=dfa8136822191, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Liver Cancer：晚期肝细胞癌的更佳一线+二线序贯疗法, objectType=article, longId=299978, objectId=e2a32999e851, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2a32999e851, replyNumber=0, likeNumber=100, createdTime=2022-03-04, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2a32999e851, moduleTitle=Liver Cancer：晚期肝细胞癌的更佳一线+二线序贯疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2a32999e851)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368220, encodeId=2c351368220ed, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=BMC Cancer：倾向评分匹配（PSM）研究表明抗PD-1联合索拉非尼较抗PD-1单药改善晚期肝细胞癌患者的预后, objectType=article, longId=294048, objectId=4fc429404878, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4fc429404878, replyNumber=0, likeNumber=87, createdTime=2022-01-17, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4fc429404878, moduleTitle=BMC Cancer：倾向评分匹配（PSM）研究表明抗PD-1联合索拉非尼较抗PD-1单药改善晚期肝细胞癌患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4fc429404878)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368219, encodeId=895813682190f, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Ther Adv Med Oncol：中肿石明教授团队回顾性研究发现仑伐替尼+特瑞普利单抗+肝动脉灌注化疗（HAIC）可改善晚期肝细胞癌患者预后, objectType=article, longId=293055, objectId=28ee293055ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28ee293055ec, replyNumber=0, likeNumber=92, createdTime=2021-12-30, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28ee293055ec, moduleTitle=Ther Adv Med Oncol：中肿石明教授团队回顾性研究发现仑伐替尼+特瑞普利单抗+肝动脉灌注化疗（HAIC）可改善晚期肝细胞癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28ee293055ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368218, encodeId=c9711368218e2, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Liver Cancer：影像学应答是伴有肉眼血管侵犯(MVI)的晚期肝细胞癌患者应用TACE+RT治疗时的显著预后指标, objectType=article, longId=221712, objectId=37eb221e1225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37eb221e1225, replyNumber=0, likeNumber=103, createdTime=2021-12-10, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37eb221e1225, moduleTitle=Liver Cancer：影像学应答是伴有肉眼血管侵犯(MVI)的晚期肝细胞癌患者应用TACE+RT治疗时的显著预后指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37eb221e1225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368217, encodeId=140b136821eab, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Liver Cancer：卡博替尼（Cabozantinib）对比安慰剂治疗晚期肝细胞癌患者的基于血清标志物的预后分析：3期临床研究CELESTIAL, objectType=article, longId=221546, objectId=86b522154637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86b522154637, replyNumber=0, likeNumber=95, createdTime=2021-12-06, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86b522154637, moduleTitle=Liver Cancer：卡博替尼（Cabozantinib）对比安慰剂治疗晚期肝细胞癌患者的基于血清标志物的预后分析：3期临床研究CELESTIAL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86b522154637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368216, encodeId=9b611368216ac, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Front Oncol：Lenvatinib(仑伐替尼，LEN)联合免疫检查点抑制剂(ICIs)治疗晚期肝细胞癌（HCC）患者的安全性和有效性, objectType=article, longId=220495, objectId=dbd22204957c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbd22204957c, replyNumber=0, likeNumber=87, createdTime=2021-11-18, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbd22204957c, moduleTitle=Front Oncol：Lenvatinib(仑伐替尼，LEN)联合免疫检查点抑制剂(ICIs)治疗晚期肝细胞癌（HCC）患者的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbd22204957c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368215, encodeId=cccc13682154f, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Liver Cancer：免疫相关不良事件(irAEs)对晚期肝细胞癌患者使用免疫检查点抑制剂(ICIs)疗效的影响, objectType=article, longId=219336, objectId=97b7219336b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97b7219336b4, replyNumber=0, likeNumber=100, createdTime=2021-10-29, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97b7219336b4, moduleTitle=Liver Cancer：免疫相关不良事件(irAEs)对晚期肝细胞癌患者使用免疫检查点抑制剂(ICIs)疗效的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97b7219336b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368214, encodeId=606b13682140c, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Front Oncol：仑伐替尼（lenvatinib）对比索拉非尼（Sorafenib）治疗晚期肝细胞癌的疗效：倾向评分匹配（PSM）分析, objectType=article, longId=219316, objectId=14432193166f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14432193166f, replyNumber=0, likeNumber=89, createdTime=2021-10-28, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14432193166f, moduleTitle=Front Oncol：仑伐替尼（lenvatinib）对比索拉非尼（Sorafenib）治疗晚期肝细胞癌的疗效：倾向评分匹配（PSM）分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14432193166f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368213, encodeId=e67813682139c, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Front Oncol：卡瑞利珠单抗联合索拉非尼vs 索拉非尼单药治疗晚期肝细胞癌（HCC）的有效性和安全性, objectType=article, longId=219191, objectId=02ce219191a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02ce219191a0, replyNumber=0, likeNumber=70, createdTime=2021-10-26, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02ce219191a0, moduleTitle=Front Oncol：卡瑞利珠单抗联合索拉非尼vs 索拉非尼单药治疗晚期肝细胞癌（HCC）的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02ce219191a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368212, encodeId=98c71368212d7, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Br J Cancer：晚期肝细胞癌患者诊断性活检的可行性分析, objectType=article, longId=218510, objectId=91142185104b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91142185104b, replyNumber=0, likeNumber=79, createdTime=2021-10-14, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91142185104b, moduleTitle=Br J Cancer：晚期肝细胞癌患者诊断性活检的可行性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91142185104b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

晚期肝细胞癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#晚期肝细胞癌# #纳武利尤单抗# #伊匹木单抗#

ASCO 2024：与仑伐替尼或索拉非尼相比，纳武利尤单抗联合伊匹木单抗一线治疗晚期肝细胞癌患者可显著改善总生存期（CheckMate -9DW 3期研究）

2024-06-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#贝伐珠单抗# #晚期肝细胞癌# #特瑞普利单抗#

CLIN CANCER RES | 特瑞普利单抗联合贝伐珠单抗作为晚期肝细胞癌一线治疗的II期临床试验

2024-05-06发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#帕博利珠单抗# #晚期肝细胞癌#

JCO：疗效良好且安全可控：帕博利珠单抗二线治疗亚洲晚期HCC患者（III期临床研究）

2024-03-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#晚期肝细胞癌# #阿替利珠单抗#

读书报告 | 晚期肝细胞癌系统治疗指南建议的批判性评价

2024-01-01发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

全文收起有几项研究显示，#咖啡#、#阿司匹林#、#他汀类药物#和#二甲双胍#的使用均与#肝细胞癌#风险降低有关。对于需要使用#免疫检查点抑制剂#治疗的#晚期肝细胞癌#，一线治疗推荐方案为#阿替利珠单抗#联合#贝伐单抗#。若患者存在胃食管和/或胃肠道出血高风险或其他贝伐珠单抗禁忌证，#度伐利尤单抗#+#Tremelimumab#可能是更合适的选择。对于存在使用免疫检查点抑制剂禁忌证的患者，如患有自身免疫性疾病或肝移植后接受免疫抑制剂治疗的患者，推荐一线治疗选择#仑伐替尼#或#索拉非尼#

Nature子刊：全球超80万人死于肝癌！咖啡、阿司匹林、他汀、二甲双胍或可预防

2023-12-16发表于威斯康星

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Clin Cancer Res：派姆单抗单药治疗初治晚期肝细胞癌

2022-05-05

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Clin Cancer Res：Pembrolizumab单药治疗晚期肝细胞癌的效果

2022-04-22

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

BMC Cancer：仑伐替尼联合PD-1抑制剂治疗晚期肝细胞癌的真实世界疗效

2022-03-25

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Clin Cancer Res：可预测晚期肝细胞癌对信迪利单抗联合IBI305治疗反应的生物标志物！

2022-03-17

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Liver Cancer：仑伐替尼联合或不联合药物洗脱微球经动脉化疗栓塞治疗不可切除晚期肝细胞癌的疗效

2022-03-13

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Liver Cancer：晚期肝细胞癌的更佳一线+二线序贯疗法

2022-03-04

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

BMC Cancer：倾向评分匹配（PSM）研究表明抗PD-1联合索拉非尼较抗PD-1单药改善晚期肝细胞癌患者的预后

2022-01-17

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Ther Adv Med Oncol：中肿石明教授团队回顾性研究发现仑伐替尼+特瑞普利单抗+肝动脉灌注化疗（HAIC）可改善晚期肝细胞癌患者预后

2021-12-30

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Liver Cancer：影像学应答是伴有肉眼血管侵犯(MVI)的晚期肝细胞癌患者应用TACE+RT治疗时的显著预后指标

2021-12-10

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Liver Cancer：卡博替尼（Cabozantinib）对比安慰剂治疗晚期肝细胞癌患者的基于血清标志物的预后分析：3期临床研究CELESTIAL

2021-12-06

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Front Oncol：Lenvatinib(仑伐替尼，LEN)联合免疫检查点抑制剂(ICIs)治疗晚期肝细胞癌（HCC）患者的安全性和有效性

2021-11-18

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Liver Cancer：免疫相关不良事件(irAEs)对晚期肝细胞癌患者使用免疫检查点抑制剂(ICIs)疗效的影响

2021-10-29

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Front Oncol：仑伐替尼（lenvatinib）对比索拉非尼（Sorafenib）治疗晚期肝细胞癌的疗效：倾向评分匹配（PSM）分析

2021-10-28

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Front Oncol：卡瑞利珠单抗联合索拉非尼vs 索拉非尼单药治疗晚期肝细胞癌（HCC）的有效性和安全性

2021-10-26

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Br J Cancer：晚期肝细胞癌患者诊断性活检的可行性分析

2021-10-14

科室
- - 订阅+
  - 更多科室
工具
服务